title: Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ cell content.
abstract: Engraftment kinetics after high-dose chemotherapy (HDC) were evaluated in patients receiving autologous peripheral blood stem cell (PBSC) infusions with a low CD34+ cell content. Forty-eight patients were infused with < 2.5 x 10(6) CD34+ cells/kg; 36 because of poor harvests and 12 because they electively received only a fraction of their harvested cells. A median of 2.12 x 10(6) CD34+ cells/kg (range, 1.17-2.48) were infused following one of seven different HDC regimens. All patients achieved absolute neutrophil counts > or = 0.5 x 10(9)/l at a median of day 11 (range, 9-16). Forty-seven patients achieved platelet counts > or = 20 x 10(9)/l at a median of day 14 (range, 8-250). Nine of 47 (19%) had platelet recovery after day 21, 4/47 (9%) after day 100 and one died on day 240 without platelet recovery. Twenty-six patients (54%) died of progressive disease in 51-762 days; 22 (46%) are alive at a median of 450 days (range, 94-1844), 17 (35%) of whom are surviving disease-free at a median of 494 days (range, 55-1263). No patient died as a direct consequence of low blood cell counts. These data demonstrate that PBSC products containing 1.17-2.48 x 10(6) CD34+ cells/kg resulted in relatively prompt neutrophil recovery in all patients but approximately 10% had delayed platelet recovery.
authors.affiliation: Clinical Trials Division, Response Oncology Inc, Memphis, TN, USA.
authors.forename: C H
authors.initials: CH
authors.lastname: Weaver
authors.forename: J
authors.initials: J
authors.lastname: Potz
authors.forename: J
authors.initials: J
authors.lastname: Redmond
authors.forename: K
authors.initials: K
authors.lastname: Tauer
authors.forename: L S
authors.initials: LS
authors.lastname: Schwartzberg
authors.forename: P
authors.initials: P
authors.lastname: Kaywin
authors.forename: R
authors.initials: R
authors.lastname: Drapkin
authors.forename: B
authors.initials: B
authors.lastname: Grant
authors.forename: P
authors.initials: P
authors.lastname: Unger
authors.forename: C
authors.initials: C
authors.lastname: Allen
authors.forename: K
authors.initials: K
authors.lastname: Longin
authors.forename: B
authors.initials: B
authors.lastname: Zhen
authors.forename: B
authors.initials: B
authors.lastname: Hazelton
authors.forename: C D
authors.initials: CD
authors.lastname: Buckner
mesh_terms: D018952:Antigens, CD34 / Q000032:analysis*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000097:blood / Q000628:therapy*; D009504:Neutrophils; D010976:Platelet Count; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous
chemical_list: D018952:Antigens, CD34